Vor Biopharma, Inc. (VOR)
NASDAQ: VOR · IEX Real-Time Price · USD
8.19 -0.21 (-2.50%)
Jan 24, 2022 4:00 PM EST - Market closed
Income Statement (Annual)
Millions USD. Fiscal year is Jan - Dec.
| Year | 2020 | 2019 | 2018 |
|---|---|---|---|
| Selling, General & Admin | 11.75 | 4.22 | 0.43 |
| Research & Development | 31.62 | 6.2 | 2.43 |
| Operating Expenses | 43.37 | 10.42 | 2.86 |
| Operating Income | -43.37 | -10.42 | -2.86 |
| Interest Expense / Income | 0 | 0.61 | 1 |
| Other Expense / Income | -0.03 | -0.19 | 0.29 |
| Pretax Income | -43.34 | -10.84 | -4.15 |
| Net Income | -43.34 | -10.84 | -4.15 |
| Preferred Dividends | 5.93 | 1.77 | 0 |
| Net Income Common | -49.26 | -12.61 | -4.15 |
| Shares Outstanding (Basic) | 214 | 115 | 88 |
| Shares Outstanding (Diluted) | 214 | 115 | 88 |
| Shares Change | 85.85% | 30.97% | - |
| EPS (Basic) | -230.57 | -109.70 | -47.30 |
| EPS (Diluted) | -230.57 | -109.70 | -47.30 |
| Free Cash Flow Per Share | -0.19 | -0.09 | -0.03 |
| EBITDA | -41.95 | -10.14 | -3.13 |
| EBIT | -43.34 | -10.23 | -3.15 |
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).